Sten R. Sörensen

Sten R. Sörensen has been the CEO of Cereno Scientific since 2015 and has extensive experience from the pharma, biotech, and finance industries. Prior to Cereno Scientific, he held senior positions in major pharma including Head of International Marketing Operations for the 10 BSEK pharma portfolio at Monsanto and Global Marketing Director for the 4 BSEK portfolio of Secondary Prevention Products, Cardiovasculars at AstraZeneca. At Monsanto and AstraZeneca, he initiated two groundbreaking preventive survival studies in heart failure, RALES and MERIT-HF, both establishing a paradigm shift for mineralocorticoid receptor (MR) antagonism and beta-blocker drug therapies in heart failure, significantly improving quality of life and life expectancy. He was also a Board member of Cereno Scientific between 2014-2016. Sten holds a bachelor’s degree in chemistry from Lund University. He is the Chairman of SARomics Biostructure and board member of SynAct Pharma.


Considered independent of the company, its management and major shareholders.